You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Lexent's technology integrates low-pass whole-genome sequencing, fragmentomics, and DNA methylation to detect early stage disease.
The firm's SmartChip platform consists of a high-throughput liquid dispenser and a PCR instrument and can provide more than 5,000 reactions in one run.
During the COVID-19 pandemic, the website has offered a list of locations providing both antibody and PCR testing.
The DXRX marketplace, planned for launch in the fourth quarter of 2020, will provide a way for pharmaceutical companies, diagnostic firms, and laboratories to collaborate.
The company's adaptive low-resource testing technology requires no instrumentation and limited equipment, making it adaptable to settings without clinical lab infrastructure.
The paper, which is not peer-reviewed, said that use of the test as a first-step screening tool would require confirmation of more than 80 percent of its results.
Only 2.5 percent of Americans have been tested for COVID-19, even as industry scrambles to increase testing capacity and a second wave of cases may hit in the fall.
On the company's earnings call on Wednesday Roche provided some details about its work on a serology test to determine immunity for patients who have had COVID-19.
Abbott's RealTime CT/NG assay is currently only cleared by the US Food and Drug Administration for use with urogenital samples.
The company is working to develop another lab-based serology test to detect IgM antibodies in people who have already had the virus.